Photodynamic therapy - Lasers and Energy Devices for the Skin - page 229

Table 10.1 Published Clinical Studies on ALA- and MAL-PDT for AKs ( Continued )

Light Source
(Wavelength
in nm)

MAL-PDT Study
Design

Incubation
Period (hr)

# Lesions Treated
(# Patients)

Reference Location Response Rate Follow-up (mo)

Szeimies (90) (2002) 1× MAL-PDT vs.

2× freeze-thaw
cryotherapy

Face, scalp, other 3, Occluded 699 AK (367 treated

by MAL-PDT) in
193 patients

Noncoherent
red light
(570-670 nm),
total light dose of
75 J/cm 2 and a
light intensity of
70-200 mW/cm 2

MAL-PDT 69% and
cryotherapy 75%

3

Freeman (91) (2003) 2× MAL-PDT vs.

2× placebo-PDT
vs. 1 freeze cycle
cryotherapy

Face and scalp 3, Occluded 763 AKs in 200

patients (295
treated by
MAL-PDT)

Noncoherent Red
light (570-670 nm)
and a total light
dose of 75 J/cm 2 ,
light intensity of
50-250 mW/cm 2

MAL-PDT 91%,
placebo-PDT 30%,
and cryotherapy
68%

3

Pariser (92) (2003) 2× MAL-PDT vs.

2× placebo-PDT

Face and scalp 3, Occluded 502 AKs (260

treated with
MAL-PDT) in
80 patients

Noncoherent red
light (wavelength
570-670 nm, light
dose of 75 J/cm 2 ,
light intensity of
50-200 mW/cm 2

MAL-PDT 89%,
placebo-PDT 38%

3

Dragieva (99) (2004) MAL-PDT in

transplant
patients,
2× MAL-PDT vs.
2× placebo-PDT
1 wk apart

Face, scalp, neck,
and extremities

3, Occluded 34 Lesional areas

comprising
129 AKs (17 areas
with 62 AKs
treated with
MAL-PDT) in
17 OTR patients

Noncoherent light
source
(600-730 nm),
light dose of
75 J/cm 2 , light
intensity of
80 mW/cm 2

MAL-PDT 13 of
17 lesional areas
with CR,
placebo-PDT
no response

4

( Continued )